Papers - MORITAKE Hiroshi
-
呼吸不全が先行した急性弛緩性脊髄炎の幼児例 Reviewed
池田 俊郎,黒木亜津子, 木許 恭宏,谷口英里奈,盛武浩
宮崎県医師会医学会誌 42 ( 1 ) 60 - 64 2019
Language：Japanese Publishing type：Research paper (scientific journal)
-
HARAO Takuro, OKAMOTO Yasuhiro, KAWANO Yoshifumi, MORITAKE Hiroshi, YAMADA Ai, KINOSHITA Mariko, SAWA Daisuke, SAITO Yusuke, KAMIMURA Sachiyo, MIYACHI Hayato, OGINO Takashi, KODAMA Yuichi
Rinsho Ketsueki 60 ( 5 ) 378 - 381 2019
Authorship：Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Hematology
Here, we report the case of a 9-year-old girl with acute myeloid leukemia (AML) developed from systemic mastocytosis (SM). She experienced bladder and rectal disturbance due to an extramedullary nodule in the paraspinal region of the sacrum. Cytogenetic and genetic analyses of leukemic cells revealed the <i>KIT</i> D816Y mutation besides t (8;21) (q22:q22) /<i>RUNX1</i>-<i>RUNX1T1</i>. Despite receiving proton beam therapy after conventional chemotherapy, the patient relapsed after 2 months. As SM-AML with the <i>KIT</i> D816 mutation in adults exhibits a poor prognosis, hematopoietic stem cell transplantation is recommended. Owing to a few reports of SM-AML in children, the standard therapy for pediatric cases has not been established to date. Based on our experience and the related literature, the prognosis of childhood SM-AML could be as poor as in adults. Hence, further investigation, including mutational analyses of the <i>KIT</i> gene, is warranted to establish a risk-oriented strategy for managing childhood SM-AML.
-
進行神経芽腫の再発との鑑別が困難であった限局性結節性過形成の2例 Reviewed
落合佳代，山田 愛，木下真理子，澤 大介，齋藤祐介，上村幸代，佐藤勇一郎，西川拓朗，岡本康裕，河野嘉文，川野正人，川野孝文，家入里志，盛武 浩
日本小児科学会雑誌 123 ( 9 ) 1400 - 1405 2019
Authorship：Lead author, Last author Language：Japanese Publishing type：Case report
-
生体腎移植後の移植腎尿管結石反復例 Reviewed
山元綾子，今村秀明，此元隆雄，上村敏雄，賀本敏行，石塚喜世伸，服部元史，清水朋一，石田英樹，田邉一成，盛武 浩
日本小児腎不全学会雑誌 39 180 - 183 2019
Authorship：Lead author, Last author Language：Japanese Publishing type：Research paper (scientific journal)
-
新生児けいれんを契機に診断された家族歴のない血友病の1例 Reviewed
河野猛嗣、児玉由紀、山下理絵、紀愛美、椎葉望、金子政時、鮫島浩、松澤聡史、大橋昌尚、堂福美佳、山田愛、木下真理子、上村幸代、盛武浩
宮崎県医師会医学会誌 42 ( 2 ) 163 - 168 2018.12
Language：Japanese Publishing type：Case report
-
血清学的異常所見やSLE臨床所見に乏しいループス腎炎疑い例 Reviewed
黒木 純, 今村 秀明, 阪口 嘉美, 此元 隆雄, 盛 武浩, 久野 敏
日本小児腎臓病学会雑誌 31 ( 2 ) 203 - 203 2018.11
Publishing type：Case report
-
KIT D816変異陽性全身性肥満細胞症から進展し傍脊髄髄外病変に陽子線治療を施行した急性骨髄性白血病 Reviewed
原尾拓朗、山田愛、木下 真理子、澤大介、齋藤祐介、上村幸代、宮地勇人、萩野尚、盛武浩
日本小児血液・がん学会雑誌 55 ( 4 ) 314 - 314 2018.10
Publishing type：Research paper (scientific journal)
-
Adalimumab for treatment of hemophagocytic syndrome following unrelated bone marrow transplantation in a boy with Behcet's disease and secondary myelodysplastic syndrome Reviewed International journal
Noguchi M, Moritake H, Kamimura S, Sonoda M, Ishimura M, Inagaki J
Bone Marrow Transplant 53 ( 9 ) 1214 - 1217 2018.9
Language：English Publishing type：Research paper (scientific journal)
-
横紋筋融解を契機に判明したCPT2欠損症の兄弟例 Reviewed
麻田 智子, 宇藤山 麻衣子, 松山 美靜代, 盛武 浩, 澤田 浩武, 原 圭一, 但馬 剛
日本先天代謝異常学会雑誌 34 214 - 214 2018.9
Publishing type：Case report
-
EVI1 confers to the metabolic reprograming associated with leukemogenesis Reviewed
59 ( 9 ) 1507 - 1507 2018.9
Publishing type：Research paper (scientific journal)
-
PLCE1遺伝子変異を認めた巣状分節性糸球体硬化症の1歳児例 Reviewed
下田 貴史, 今村 秀明, 此元 隆雄, 中西 啓太, 野津 寛大, 飯島 一誠, 阪口 嘉美, 久野 敏, 盛武 浩
日本小児腎不全学会雑誌 38 197 - 200 2018.7
Language：Japanese Publishing type：Case report
-
軽症溶血性尿毒症症候群後に紫斑病性腎炎を発症した児の腎病理像 Reviewed
黒木 純, 今村 秀明, 阪口 嘉美, 田中 悦子, 織田 真悠子, 此元 隆雄, 久野 敏, 盛武 浩
日本小児腎不全学会雑誌 38 214 - 216 2018.7
Language：Japanese Publishing type：Research paper (scientific journal)
-
Shimada A., Iijima-Yamashita Y., Tawa A., Tomizawa D., Yamada M., Norio S., Watanabe T., Taga T., Iwamoto S., Terui K., Moritake H., Kinoshita A., Takahashi H., Nakayama H., Koh K., Goto H., Kosaka Y., Saito A., Kiyokawa N., Horibe K., Hara Y., Oki K., Hayashi Y., Tanaka S., Adachi S.
International Journal of Hematology 107 ( 5 ) 586 - 595 2018.5
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：International Journal of Hematology
© 2018, The Japanese Society of Hematology. Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42.2 and 36.8%, respectively. The 5-year disease-free survival rate among 29 patients without induction failure was 58.4%. We defined the allelic ratio (AR) of FLT3-ITD to WT > 0.7 as high. Significant differences were found in OS (AR-high, 20% vs. AR-low, 66%, p < 0.001) and EFS (13 vs. 50%, p = 0.004). All five patients with concurrent NPM1 mutations survived, while seven of eight patients who expressed the NUP98-NSD1 chimera failed to achieve 1CR and died. Multivariate analysis revealed that AR > 0.7 and expression of the NUP98-NSD1 chimera strongly impacted OS and EFS. Although all the AMLFLT3-ITD patients received HSCT at 1CR, the treatment outcome of AMLFLT3-ITD patients did not improve compared with those in a previous study. Heterogeneity was observed among AMLFLT3-ITD patients.
-
代理ミュンヒハウゼン症候群による食塩中毒が疑われた重症心身障害者例 Reviewed
高村 一成, 今村 秀明, 谷口 英里奈, 木許 恭宏, 池田 俊郎, 此元 隆雄, 日高 倫子, 大山 龍介, 盛武 浩
日本小児体液研究会誌 10 39 - 43 2018.5
Language：Japanese Publishing type：Research paper (scientific journal)
-
Diagnosis of pediatric neuroblastoma by urine cytology: A case report. Reviewed
Nishikawa S., Noguchi H., Tokumitsu T., Ohno A., Moriguchi-Goto S., Maekawa K., Asada Y., Moritake H., Kinoshita M., Yamada A., Takamura K., Sato Y.
Diagnostic cytopathology 46 ( 3 ) 280 - 283 2018.3
Language：English Publishing type：Research paper (scientific journal)
DOI： 10.1002/dc.23831
-
Kinoshita M., Yamada A., Sawa D., Kamimura S., Miyachi M., Moritake H.
Pediatric Blood and Cancer 65 e26750 2018.1
Authorship：Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Pediatric Blood and Cancer
© 2017 Wiley Periodicals, Inc. A 3-year-old male presented with a large retroperitoneal mass and multiple metastases. Biopsy results suggested alveolar rhabdomyosarcoma bearing a methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. Serum microRNA-206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC). Replacement of vincristine, irinotecan, and temozolomide (VIT) for VAC induced a marked tumor reduction and normalization of the miR-206 levels. The patient completed 14 cycles of VIT with local radiotherapy and has been in remission for 31 months. Temozolomide could be effective for tumors with a methylated MGMT gene promoter. Individualized therapy is warranted for such patients.
DOI： 10.1002/pbc.26750
-
Diagnosis, surveillance, and management of familial leukemia Reviewed
MORITAKE Hiroshi
Rinsho Ketsueki 59 ( 10 ) 2290 - 2299 2018
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Hematology
Recently, the modern technique of comprehensive genomic analysis has identified both somatic mutations originating from tumor cells and germline mutations as causative genes of inherited familial leukemias among which Fanconi anemia and Li-Fraumeni syndrome are well known. Pathogenic germline mutations occur in various pathways, affecting DNA repair, ribosome biogenesis, telomere biology, hematopoietic transcription factors, tumor suppressors, neutrophil development, and other critical cellular processes. The clinical manifestations of germline mutations present a wide phenotypic spectrum of patients displaying congenital anomalies, early-onset myelodysplastic syndrome, or no medical problems until the developing leukemia. The use of genetic tests to identify these affected persons will significantly benefit cancer surveillance and subsequent therapeutic interventions. Although familial leukemia treatment usually focuses on children, it is important for clinicians to recognize that familial leukemias can occur at any age, even among older adults. Genetic counseling after diagnosis is essential, and an immediate referral to experts in each disease is recommended.
-
けいれん重積型急性脳症と鑑別を要した乳児揺さぶり症候群の１例 Reviewed
服部 洋平,門田 善仁,東 美菜子,陣内 崇,盛武 浩,平井 俊範
宮崎県医師会医学会誌 42 207 - 211 2018
Language：Japanese Publishing type：Case report
-
小児急性リンパ性白血病のvery late relapse例の予後 九州・山口小児がん治療研究グループ(KYCCSG)ALL 96/02研究 Reviewed
野口 磨依子, 稲垣 二郎, 岡本 康裕, 古賀 友紀, 大園 秀一, 新小田 雄一, 中山 秀樹, 盛武 浩, 堀田 紀子, 糸長 伸能, 野村 優子, 下之段 秀美, 市村 卓也, 日高 靖文, 河野 嘉文
日本小児血液・がん学会雑 54 ( 5 ) 393 - 397 2018
Language：Japanese Publishing type：Research paper (scientific journal)
-
Nakayama H., Tomizawa D., Tanaka S., Iwamoto S., Shimada A., Saito A., Yamashita Y., Moritake H., Terui K., Taga T., Matsuo H., Kosaka Y., Koh K., Hosoi H., Kurosawa H., Isoyama K., Horibe K., Mizutani S., Adachi S.
Pediatrics International 59 1046 - 1052 2017.10
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Pediatrics International
© 2017 Japan Pediatric Society Background: The combination of fludarabine (Flu), high-dose cytarabine (Ara-C) and granulocyte colony-stimulating factor (G-CSF; FLAG), with anthracyclines has become standard chemotherapy for refractory acute myeloid leukemia (AML) in European children and adults. To clarify the efficacy and the safety of FLAG-idarubicin (IDA) for children prospectively, we planned a multicenter phase II study (AML-R11) by the Japanese Pediatric Leukemia/Lymphoma Study Group. Methods: Patients with AML aged between 2 and 20 years old, who had the first bone marrow (BM) relapse or induction failure, were enrolled. The FLAG-IDA regimen consisted of Flu 30 mg/m 2 for 5 days, Ara-C 2 g/m 2 for 5 days, G-CSF (lenograstim) 5 μg/kg for 6 days and IDA 10 mg/m 2 for 3 days. The primary endpoint was remission rate after therapy. Results: Due to drug supply issues, the trial was suspended after the inclusion of seven eligible patients. There were six cases of early relapse within 1 year of the first remission. All seven patients completed the therapy and no early death was observed. Hematological toxicity was common, and one patient developed grade 4 non-hematological toxicity of bacterial meningitis. Although only one patient with late relapse achieved complete remission, minimal residual disease was positive on both flow cytometry and Wilms’ tumor 1 mRNA. Two patients were alive in remission following hematopoietic stem cell transplantation, whereas the other five patients died of either the disease or treatment-related causes. Conclusion: FLAG-IDA might be tolerable for children with refractory AML although the efficacy should be further investigated.
DOI： 10.1111/ped.13378